Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL432268 | 0.81 | RAB9A (0.32) | RAB9A | |
| SCHEMBL7113519 | 0.79 | KDM4E (0.39) | KDM4ECYP1A2CYP2D6 | |
| SCHEMBL17536794 | 0.77 | MEN1 (0.30) | — | |
| SCHEMBL432707 | 0.74 | KDM1A (0.34) | KDM4E | |
| SCHEMBL9690018 | 0.72 | — | — | |
| SCHEMBL6770040 | 0.69 | SLC6A4 (0.36) | — | |
| SCHEMBL2661683 | 0.68 | ALDH1A1 (0.39) | ALDH1A1HPGDKDM4EPKMALOX12 | |
| SCHEMBL7564380 | 0.63 | RECQL (0.33) | CYP1A2CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL14367899 | 0.61 | TSHR (0.33) | RAB9ACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4938 | 0.60 | NOS1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140275076-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | BOSTON BIOMEDICAL, INC. | 2014-09-18 | — | — | US | claimed |
| US-7666871-B2 | 3-Methyl-6-(4-{5-methyl-4-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-oxazol-2-yl}-phenyl)-pyridazine; for treatment of obesity, cognitive deficiencies, narcolepsy | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | claimed |
| CN-100522957-C | Sulfonium salt photinitiators and use thereof | NAT STARCH CHEM INVEST (US) | 2009-08-05 | — | — | CN | claimed |
| EP-1786790-B1 | OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2009-06-03 | — | — | EP | claimed |
| CN-100474110-C | Selected acid generators and their use in radiation-sensitive element imaging processes | EASTMAN KODAK CO (US) | 2009-04-01 | — | — | CN | claimed |
| US-20070197604-A1 | Oxazole derivatives as histamine h3 receptor agents,preparation and therapeutic uses | ELI LILLY AND COMPANY | 2007-08-23 | — | — | US | claimed |
| EP-1786790-A1 | OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-05-23 | — | — | EP | claimed |
| WO-2006019833-A1 | OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-02-23 | — | — | WO | claimed |
| CN-1671387-A | Aryl substituted hydantoin compounds and their use as sodium channel blockers | EURO CELTIQUE SA (LU) | 2005-09-21 | — | — | CN | claimed |
| CN-1671672-A | Aryl-substituted benzimidazoles and their use as sodium channel blockers | EURO CELTIQUE SA (LU) | 2005-09-21 | — | — | CN | claimed |
| CN-1637052-A | Sulfonium salt photinitiators and use thereof | NAT STARCH CHEM INVEST (US) | 2005-07-13 | — | — | CN | claimed |
| WO-2002074742-A2 | CDK-INHIBITORY INDIRUBIN DERIVATIVES HAVING AN INCREASED SOLUBILITY | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-09-26 | — | — | WO | claimed |
| US-20210240077-A1 | PHOTOSENSITIVE COMPOSITIONS, PREPARATION METHODS THEREOF, AND QUANTUM DOT POLYMER COMPOSITE PATTERN PRODUCED THEREFROM | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2021-08-05 | — | — | US | disclosed |
| US-10990006-B2 | Photosensitive compositions, preparation methods thereof, and quantum dot polymer composite pattern produced therefrom | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2021-04-27 | — | — | US | disclosed |
| CN-105452398-B | Composition for ink, ink jet recording method and tingle body using this composition for ink | 日本化药株式会社 | 2018-07-10 | — | — | CN | disclosed |
| US-20170176854-A1 | PHOTOSENSITIVE COMPOSITIONS, PREPARATION METHODS THEREOF, AND QUANTUM DOT POLYMER COMPOSITE PATTERN PRODUCED THEREFROM | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-06-22 | — | — | US | disclosed |
| EP-1042290-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000050396-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-08-31 | — | — | WO | disclosed |
| CN-1254288-A | Condensation polymer composition for preventing pregnancy | PROCEPT INC (US) | 2000-05-24 | — | — | CN | disclosed |
| WO-1999025687-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 1999-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197604-A1 | Oxazole derivatives as histamine h3 receptor agents,preparation and therapeutic uses | HCRTR1, HRH3, HCRTR2 | ALDH1A1 1633/4885HPGD 1930/4885KDM4E 486/4885 |
| US-20140275076-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | CYP2C9, DHRS9, HTR3B | ALDH1A1 385/4885HPGD 474/4885KDM4E 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.